TREACE JAMES T 4
4 · TREACE MEDICAL CONCEPTS, INC. · Filed Mar 29, 2024
Insider Transaction Report
Form 4
TREACE JAMES T
Director
Transactions
- Sale
Common Stock
2022-11-15$21.18/sh−1,600$33,890→ 1,038,341 total - Sale
Common Stock
2022-11-15$21.97/sh−200$4,394→ 1,038,141 total - Sale
Common Stock
2022-11-15$24.02/sh−1,700$40,828→ 1,036,441 total - Sale
Common Stock
2022-11-15$20.12/sh−46,500$935,580→ 1,039,941 total
Holdings
- 556,183(indirect: By Spouse)
Common Stock
Footnotes (4)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- [F2]The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $19.55 to $20.4600 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $20.6200 to $21.5400 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $23.6100 to $24.6000 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.